Crescent Biopharma Inc

First patient dose of Crescent Biopharma’s CR‑001 bispecific antibody is now in the ASCEND Phase 1/2 trial, a global study targeting advanced solid tumors and combining PD‑1 and VEGF blockade for safer, potentially more effective cancer treatment.

Investors eye Crescent Biopharma’s struggle: a biotech firm hit by a steep stock decline, negative P/E and unmet drug‑commercialization goals, questioning its long‑term viability.

Crescent Biopharma Inc. is a biotechnology company focused on developing molecule drugs for blood cancers and inflammatory conditions, positioning itself for growth and impact in the healthcare industry.